Tomoxetine: Phase II data; Phase III

Data from 2 placebo-controlled U.S. Phase II studies in a total of 291 pediatric patients showed that a twice daily dose of tomoxetine significantly improved ADHD symptoms in most patients compared to placebo, and had comparable efficacy to Novartis AG's Ritalin methylphenidate. A total of 7 percent of patients on tomoxetine reported insomnia compared to 27 percent of the Ritalin group and 7 percent of the placebo group, and anorexia was observed with both tomoxetine and Ritalin. ...